Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04702880 · ClinicalTrials.gov registry record · Phase 2

A Study of BMS-986012 in Combination With Carboplatin, Etoposide, and Nivolumab as First-line Therapy in Extensive-stage Small Cell Lung Cancer

A Phase 2 study of Extensive-stage Small-cell Lung Cancer, sponsored by Bristol-Myers Squibb.

Active
Registry status
Phase 2
Development phase
120
Enrollment target
20
Study locations

NCT04702880: Active Phase 2 study of Extensive-stage Small-cell Lung Cancer, sponsored by Bristol-Myers Squibb.

NCT04702880 is a Phase 2 study of Extensive-stage Small-cell Lung Cancer that is active but no longer recruiting, run by Bristol-Myers Squibb. The registered enrollment target is 120 participants, below the 171-participant average among 25 other Extensive-stage Small-cell Lung Cancer trials with a reported enrollment target (30% lower). The trial reports 20 study locations across 15 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04702880, a Phase 2 study of Extensive-stage Small-cell Lung Cancer, is active but no longer recruiting, sponsored by Bristol-Myers Squibb.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
120 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to demonstrate that treatment with BMS-986012 in combination with carboplatin, etoposide, and nivolumab will have acceptable safety and tolerability and will improve progression-free survival compared with carboplatin, etoposide, and nivolumab alone in newly diagnosed participants with extensive-stage small cell lung cancer (ES-SCLC).

Primary Outcome

An adverse event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a clinical investigation participant administered study treatment that does not necessarily have a causal relationship with this treatment.

Conditions Studied

Extensive-stage Small-cell Lung Cancer

Interventions

  • DRUG Carboplatin
  • DRUG Etoposide
  • BIOLOGICAL Nivolumab
  • BIOLOGICAL BMS-986012

Study Locations (20)

Other

  • Local Institution - 0034 - Ghent
  • Local Institution - 0050 - Liège
  • Local Institution - 0036 - Athens
  • Local Institution - 0038 - Athens

Ohio

  • Local Institution - 0060 - Cincinnati
  • Local Institution - Cincinnati
  • Local Institution - 0067 - Cleveland

Alabama

  • Local Institution - 0075 - Birmingham

New Jersey

  • Local Institution - 0022 - Hackensack

North Carolina

  • Local Institution - 0002 - Durham

Tennessee

  • Local Institution - 0081 - Nashville

Texas

  • Local Institution - Dallas

New South Wales

  • Local Institution - 0003 - Westmead

Trial Details

FieldValue
Enrollment Target 120 participants
Start Date 2021-03-17
Est. Completion 2025-12-31
Phase Phase 2
Bristol-Myers Squibb

1,025 total trials

What the registry record for NCT04702880 still lists

NCT04702880 is an interventional study that assigns participants to a tested intervention. The registered 120 participants enrollment target is mid-sized for trials with a published cap, below the 171-participant average among 25 other Extensive-stage Small-cell Lung Cancer trials with a reported enrollment target (30% lower).

The record links to 1 condition, with Extensive-stage Small-cell Lung Cancer appearing as the primary indexed condition, and to 4 interventions - of which Carboplatin is the first listed.

NCT04702880 names 20 study sites across 15 states, led by Other, Ohio, Alabama.

Frequently Asked Questions

What is clinical trial NCT04702880 about?

NCT04702880 is a clinical study titled "A Study of BMS-986012 in Combination With Carboplatin, Etoposide, and Nivolumab as First-line Therapy in Extensive-stage Small Cell Lung Cancer". The purpose of this study is to demonstrate that treatment with BMS-986012 in combination with carboplatin, etoposide, and nivolumab will have acceptable safety and tolerability and will improve progression-free survival compared with carboplatin, etoposide, and nivolumab alone in newly diagnosed pa...

What is the current status of trial NCT04702880?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 120 participants. The study started on 2021-03-17. Estimated completion is 2025-12-31.

What conditions does trial NCT04702880 study?

This clinical trial studies the following conditions: Extensive-stage Small-cell Lung Cancer.

What interventions are being tested in trial NCT04702880?

The interventions under investigation include: Carboplatin (DRUG), Etoposide (DRUG), Nivolumab (BIOLOGICAL), BMS-986012 (BIOLOGICAL).

Who is sponsoring clinical trial NCT04702880?

This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04702880 being conducted?

This trial has 20 study locations across Alabama, New Jersey, North Carolina, Ohio, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Extensive-stage Small-cell Lung Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04702880's enrollment target sits among peer trials

120 13th of 25 higher than 13 of 25 other Extensive-stage Small-cell Lung Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Extensive-stage Small-cell Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01174108 · 120 participants · Phase 2

    Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells

  • NCT01627301 · 120 participants · NA

    Sympathetic Overactivity in Post-traumatic Stress Disorder

  • NCT02025023 · 120 participants · Phase 3

    Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study

  • NCT02128906 · 120 participants · Phase 2

    Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT04702880, the US trial registry maintained by the National Library of Medicine. NCT04702880 (mid enrollment · wide site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.